<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2639">
  <stage>Registered</stage>
  <submitdate>18/01/2010</submitdate>
  <approvaldate>18/01/2010</approvaldate>
  <nctid>NCT01052142</nctid>
  <trial_identification>
    <studytitle>Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma</studytitle>
    <scientifictitle>A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Lipovaxin-MM-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Lipovaxin-MM

Experimental: Lipovaxin-MM - 


Other interventions: Lipovaxin-MM
Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint>Within 84 days after first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Immunogenicity - antigen specific immune responses will be monitored</outcome>
      <timepoint>Within 42 days of first dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-cancer activity (RECIST criteria) - assessed every 6 weeks of study</outcome>
      <timepoint>Within 84 days of first dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Patients with incurable stage IV malignant melanoma for which no standard or curative
             therapy exist OR patients locoregionally recurrent melanoma (including local
             metastases, in transit metastases and satellitosis) where surgery is not the best
             therapeutic option.

          -  Must be able and willing to provide written informed consent.

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1.

          -  Life expectancy of =12 weeks.

          -  Female subjects must be of non-child-bearing potential or using appropriate
             contraception.

          -  Positive test for cell mediated immunity.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Brain metastases or spinal cord compression, unless treatment was completed at least 4
             weeks before entry and stable without steroid treatment for at least 4 weeks.

          -  Previous immunotherapy (except IL-2 or interferon-based therapy) for melanoma.

          -  Inadequate bone marrow reserve.

          -  Serum bilirubin =1.2 times the upper limit of normal.

          -  In absence of metastases, liver transaminase levels greater than 1.5 times the upper
             limit of normal.

          -  If metastases are evident, liver transaminase levels 2.5 times the upper limit of
             normal will be acceptable.

          -  Inadequate renal function.

          -  Evidence of severe or uncontrolled systemic diseases.

          -  Unresolved toxicity =CTC Grade 2 from previous anti-cancer therapy except alopecia (if
             applicable) unless agreed that the patient can be entered after discussion with the
             Medical Monitor.

          -  Participation in a trial of an investigational agent within the prior 30 days.

          -  HIV infection.

          -  Immunosuppressive therapy including corticosteroids within 4 weeks of screening.

          -  Pregnant or breast-feeding females.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Pain &amp; Anaesthesia Research Clinic - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Lipotek Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Adelaide Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Trident Clinical Research Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is
      safe and effective in improving the body's ability to destroy cancer cells in patients with
      metastatic melanoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01052142</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Brown, MBBS FRACP FRCPA</name>
      <address>Royal Adelaide Hospital Cancer Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>